June 18, 2014 | Israeli biotechnology company Brainstorm Cell Therapeutics announced that it raised $10.5 million in private placement, or a non-public offering. The funds from the offering will go towards the phase II clinical trials for an ALS (Lou Gehrig’s disease) treatment that the company has developed. Brainstorm Cell’s treatment is called NurOwn for both ALS, Multiple Sclerosis and Parkinson’s disease, but now the company is considering examining its use for the treatment of autism.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

AI Startup Helps Doctors Analyze Heart Scans
February 08, 2023

AI Monitors High-Speed Conveyor Belts For Defects
February 08, 2023

Israel Hi-Tech Group In Rescue Mission To Turkey
February 08, 2023

Israeli Startup Tests Cancer Treatment With Pharma Giant
February 07, 2023
Facebook comments